dc.contributor.author | Fosheim, Ingrid Knutsdotter | |
dc.contributor.author | Jacobsen, Daniel Pitz | |
dc.contributor.author | Sugulle, Meryam | |
dc.contributor.author | Alnæs-Katjavivi, Patji | |
dc.contributor.author | Fjeldstad, Heidi | |
dc.contributor.author | Ueland, Thor | |
dc.contributor.author | Lekva, Tove | |
dc.contributor.author | Staff, Anne Cathrine | |
dc.date.accessioned | 2023-03-20T07:11:57Z | |
dc.date.available | 2023-03-20T07:11:57Z | |
dc.date.issued | 2022-11-09 | |
dc.description.abstract | BACKGROUND: Hypertensive disorders of pregnancy (preeclampsia,
gestational hypertension, and chronic hypertension), diabetes mellitus,
and placental dysfunction confer an increased risk of long-term maternal
cardiovascular disease. Preeclampsia is also associated with acute atherosis that involves lesions of uteroplacental spiral arteries, resembling early
stages of atherosclerosis. Serum amyloid A1 is involved in hypercoagulability and atherosclerosis and may aggregate into amyloid—aggregations
of misfolded proteins. Pregnancy zone protein may inhibit amyloid aggregation. Amyloid is involved in Alzheimer's disease and cardiovascular disease; it has been identified in preeclampsia, but its role in preeclampsia
pathophysiology is unclear.<p>
<p>OBJECTIVE: We hypothesized that serum amyloid A1 would be
increased and pregnancy zone protein decreased in hypertensive disorders
of pregnancy and diabetic pregnancies and that serum amyloid A1 and
pregnancy zone protein would correlate with placental dysfunction
markers (fetal growth restriction and dysregulated angiogenic biomarkers)
and acute atherosis.
<p>STUDY DESIGN: Serum amyloid A1 is measurable in both the serum
and plasma. In our study, plasma from 549 pregnancies (normotensive,
euglycemic controls: 258; early-onset preeclampsia: 71; late-onset preeclampsia: 98; gestational hypertension: 30; chronic hypertension: 9; diabetes mellitus: 83) was assayed for serum amyloid A1 and pregnancy
zone protein. The serum levels of angiogenic biomarkers soluble fms-like
tyrosine kinase-1 and placental growth factor were available for 547
pregnancies, and the results of acute atherosis evaluation were available
for 313 pregnancies. The clinical characteristics and circulating biomarkers were compared between the pregnancy groups using the MannWhitney U, chi-squared, or Fisher exact test as appropriate. Spearman’s
rho was calculated for assessing correlations.
<p>RESULTS: In early-onset preeclampsia, serum amyloid A1 was
increased compared with controls (17.1 vs 5.1 mg/mL, P<.001), whereas
pregnancy zone protein was decreased (590 vs 892 mg/mL, P=.002).
Pregnancy zone protein was also decreased in diabetes compared with
controls (683 vs 892 mg/mL, P=.01). Serum amyloid A1 was associated
with placental dysfunction (fetal growth restriction, elevated soluble fmslike tyrosine kinase-1 to placental growth factor ratio). Pregnancy zone
protein correlated negatively with soluble fms-like tyrosine kinase-1 to placental growth factor ratio in all study groups. Acute atherosis was not
associated with serum amyloid A1 or pregnancy zone protein.
<p>CONCLUSION: Proteins involved in atherosclerosis, hypercoagulability, and protein misfolding are dysregulated in early-onset preeclampsia
and placental dysfunction, which links them and potentially contributes to
future maternal cardiovascular disease. | en_US |
dc.identifier.citation | Fosheim, Jacobsen, Sugulle, Alnæs-Katjavivi, Fjeldstad, Ueland, Lekva, Staff. Serum amyloid A1 and pregnancy zone protein in pregnancy complications and correlation with markers of placental dysfunction. American Journal of Obstetrics & Gynecology MFM (AJOG MFM). 2022;5(1) | en_US |
dc.identifier.cristinID | FRIDAID 2132266 | |
dc.identifier.doi | 10.1016/j.ajogmf.2022.100794 | |
dc.identifier.issn | 2589-9333 | |
dc.identifier.uri | https://hdl.handle.net/10037/28792 | |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.journal | American Journal of Obstetrics & Gynecology MFM (AJOG MFM) | |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2022 The Author(s) | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | en_US |
dc.rights | Attribution 4.0 International (CC BY 4.0) | en_US |
dc.title | Serum amyloid A1 and pregnancy zone protein in pregnancy complications and correlation with markers of placental dysfunction | en_US |
dc.type.version | publishedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |